Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals


August 19, 2010 6:17 am | News | Comments

Bristol-Myers Squibb Company announced that the FDA has accepted, for filing and review, the Biologics License Application for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated.


J & J Appoints Quality Czar

August 19, 2010 6:13 am | News | Comments

Johnson & Johnson is creating a new position to oversee companywide quality, manufacturing and compliance issues and appointing chief quality officers for each of its three major business units.


Stem Cells Restore Mobility From Spinal Cord Injury

August 19, 2010 6:10 am | News | Comments

StemCells, Inc., announced the publication of new preclinical data demonstrating that the company’s proprietary human neural stem cells restore lost motor function in mice with chronic spinal cord injury.


Endo Gets Reprieve From Opana Generic

August 19, 2010 6:01 am | News | Comments

Shares of Endo Pharmaceuticals Holdings Inc. jumped this week after an analyst said Endo can keep generic versions of its painkiller Opana ER from being approved, which would sustain sales until Endo starts selling a new version.


Color-Neutralizing Film

August 18, 2010 8:25 am | Drug Discovery & Development | Product Releases | Comments

One of the prerequisites for the success of a clinical trial is to ensure that the effective drugs and placebos involved cannot be distinguished from each other. Schreiner MediPharm has now developed a solution which neutralizes the appearance of liquids in transparent containers.


Control Assay

August 18, 2010 8:05 am | Product Releases | Comments

Bio-Rad Laboratories introduces the SsoFast EvaGreen control assay, a prepackaged kit that helps labs conveniently verify their real-time PCR instrument performance.


Genetix Granted ClonePix Patent

August 18, 2010 8:02 am | News | Comments

Genetix announces that it was granted a patent, US 7,776,584. Aspects of this patent are incorporated into ClonePix FL, which is used for the screening and selection of cell lines producing biopharmaceuticals.


MedImmune Evaluating Phylogica's Peptide Library

August 18, 2010 7:56 am | News | Comments

Phylogica Ltd, a public Australian drug discovery company, announced that they have entered into an agreement with MedImmune to evaluate Phylogica’s proprietary Phylomer peptide library for novel antimicrobial peptides.


Jazz Pharma Drug Treats Fibromyalgia

August 18, 2010 7:47 am | by Matthew Perrone | News | Comments

Shares of Jazz Pharmaceuticals Inc. jumped after federal health officials said one of its drugs appears effective for treating a chronic pain disorder.


Special Sugars Allow Immune Evasion

August 18, 2010 7:44 am | News | Comments

A special set of sugars found on some disease-causing pathogens helps those pathogens fight the body's natural defenses as well as vaccines, say two Iowa State University researchers.


New Means of Tumor Drug Resistance Found

August 18, 2010 7:22 am | News | Comments

A team of scientists published results of a study that suggests new ways in which tumor cells develop resistance to one of the most successful targeted therapies, the small-molecule drug Tarceva.


Tanner Signs Distribution Deal for MDR-TB Drug

August 18, 2010 7:10 am | News | Comments

Tanner Pharmaceuticals Inc. announced that it has entered into an exclusive agreement with the Chao Center for the rights to distribute cycloserine, a drug to treat multidrug-resistant tuberculosis, in the Latin American market.


XOMA Sells Stake in CIMZIA to Fund XOMA 052

August 18, 2010 7:05 am | News | Comments

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has sold its royalty interest in CIMZIA marketed by UCB S.A. for $4 million to an undisclosed buyer.


Xenon Starts Phase 2 Trial for XEN402

August 18, 2010 7:01 am | News | Comments

Xenon Pharmaceuticals Inc. announced that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of postherpetic neuralgia.


FDA Approves Abbott sNDA

August 18, 2010 6:58 am | News | Comments

Abbott announced that the U.S. Food and Drug Administration approved the supplemental New Drug Application for CREON Delayed-Release Capsules that now includes dosing guidance specific to patients with exocrine pancreatic insufficiency.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.